The offering provides a substantial cash runway to fund pivotal trials for ERAS-0015 through key catalysts in 2027, including a potential registration-enabling NSCLC trial and Phase 3 PDAC trial. The 10% dilution is a near-term headwind, but the strong Phase 1 data and accelerated development plans could support the stock if data continues to impress. Monitor for further clinical updates and any insider selling post-lockup expiration (60 days).
Drugs in focus
ERAS drug pipeline →ERAS-0015
◆ Mixed Named in this 424B5- Impact
- Phase
- Phase 1
- Time to market
- ~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
- Next catalyst
- None dated
What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 15 $21.26entry
- T+1 · 4mo ago −10.54%α −9.99% · $19.02
- T+5 · 4mo ago −8.23%α −7.25% · $19.51
- T+20 · 3mo ago −12.61%α −14.95% · $18.58
- T+60 · 6w ago −27.28%α −29.81% · $15.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca is conducting a $550M follow-on offering of 31.4M shares at $17.50 (2.2% discount to last sale), with net proceeds of ~$516M to fund R&D for its RAS/MAPK pipeline. The filing also discloses encouraging updated Phase 1 data for lead candidate ERAS-0015, showing a 57% uORR8wk in 2L KRAS G12X PDAC at the 32mg RDE dose. The combination of dilutive financing and positive clinical data creates a mixed signal for the stock.
Key Facts
- Offering of 31,428,572 shares at $17.50 per share, raising $550M in gross proceeds (~$516M net)
- Underwriters have a 30-day option to purchase an additional 4,714,285 shares
- Post-offering shares outstanding: 342,235,460 (or 346,949,745 if overallotment exercised)
- New investors face immediate dilution of $14.84 per share (85% of offering price)
- Net tangible book value increases from $1.27 to $2.66 per share post-offering
- Updated Phase 1 data for ERAS-0015 shows 57% uORR8wk (N=7) at 32mg QD in 2L KRAS G12X PDAC
- ERAS-0015 combination with panitumumab cleared first dose escalation cohort with no DLTs
- Company plans to initiate potentially registration-enabling trial in NSCLC in H1 2027 and Phase 3 pivotal trial in PDAC in 2027
- Proceeds to fund R&D, working capital, and potential in-licensing/acquisitions
- $200M ATM facility with Jefferies remains available
Financial Impact
Gross proceeds of $550M ($516M net) from sale of 31.4M shares at $17.50; immediate dilution of $14.84 per share for new investors; post-offering cash position increases to ~$909.5M in net tangible book value
Risk Factors
- Immediate and substantial dilution of 85% of offering price for new investors
- Clinical-stage biotech with no approved products; ERAS-0015 data is preliminary and from small sample sizes
- Potential for further dilution from $200M ATM facility and outstanding options (58.4M shares)
- Competitive landscape for RAS/MAPK-targeted therapies is intense
- One Grade 5 pneumonitis event reported in safety data raises toxicity concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-303352 |
| Document: d116467dexfilingfees.htm | 0001193125-26-303352 |
| Document: 0001193125-26-303352-index-headers.html | 0001193125-26-303352 |
| Document: 0001193125-26-303352-index.html | 0001193125-26-303352 |
| Document: 0001193125-26-303352.txt | 0001193125-26-303352 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers